{"entity":{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of KL-A167, Carboplatin, Etoposide in small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"SKB500 Combinations in Patients With Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07296809 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 80 participants planned, started 2026-01-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection, Etoposide Injection. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07296809","url":"https://clinicaltrials.gov/study/NCT07296809"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["kl-a167","carboplatin","etoposide"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07296809","phase":"2","setting":"A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct07296809/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}